Inari Medical initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Inari Medical (NARI) with an Outperform rating and $75 price target Inari is a leader in the thrombectomy for the treatment of deep vein thrombosis and pulmonary embolism, notes the analyst, who says “competition is tough,” but adds that the market is still underpenetrated in the U.S. Ongoing clinical trials provide potential acceleration ahead while Inari also has a number of new opportunities beyond DVT/PE that the firm believes can drive “solid revenue growth and multiple expansion,” the analyst tells investors.